|
1
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type: Male:
Female differences diminishing and adenocarcinoma rates rising. Int
J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and
Manegold C: Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab as first-line therapy for nonsquamous
non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jorge SEDC, Kobayashi SS and Costa DB:
Epidermal growth factor receptor (EGFR) mutations in lung cancer:
Preclinical and clinical data. Braz J Med BiolRes. 47:929–939.
2014. View Article : Google Scholar
|
|
5
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motoi N, Szoke J, Riely GJ, Seshan VE,
Kris MG, Rusch VW, Gerald WL and Travis WD: Lung adenocarcinoma:
Modification of the 2004 WHO mixed subtype to include the major
histologic subtype suggests correlations between papillary and
micropapillary adenocarcinoma subtypes, EGFR mutations and gene
expression analysis. Am J Surg Pathol. 32:810–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yatabe Y, Koga T, Mitsudomi T and
Takahashi T: CK20 expression, CDX2 expression, K-ras mutation and
goblet cell morphology in a subset of lung adenocarcinomas. J
Pathol. 203:645–652. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riely GJ, Marks J and Pao W: KRAS
mutations in non-small cell lung cancer. Proc Am Thorac Soc.
6:201–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berge EM, Lu X, Maxson D, Barón AE,
Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M and Camidge
DR: Clinical benefit from pemetrexed before and after crizotinib
exposure and from crizotinib before and after pemetrexed exposure
in patients with anaplastic lymphoma kinase-positive non-small-cell
lung cancer. Clinical Lung Cancer. 14:636–643. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Warth A, Muley T, Meister M, Stenzinger A,
Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and
Weichert W: The novel histologic international association for the
study of lung cancer/American thoracic society/European respiratory
society classification system of lung adenocarcinoma is a
stage-independent predictor of survival. J Clin Oncol.
30:1438–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Russell PA, Barnett SA, Walkiewicz M,
Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D
and John T: Correlation of mutation status and survival with
predominant histologic subtype according to the new IASLC/ATS/ERS
lung adenocarcinoma classification in stage III (N2) patients. J
Thorac Oncol. 8:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshizawa A, Sumiyoshi S, Sonobe M,
Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H
and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma
classification for prognosis and association with EGFR and KRAS
gene mutations: Analysis of 440 Japanese patients. J Thorac
Oncology. 8:52–61. 2013. View Article : Google Scholar
|
|
15
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida A, Tsuta K, Nakamura H, Kohno T,
Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K
and Tsuda H: Comprehensive histologic analysis of ALK-rearranged
lung carcinomas. Am J Surg Pathol. 35:1226–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jokoji R, Yamasaki T, Minami S, Komuta K,
Sakamaki Y, Takeuchi K and Tsujimoto M: Combination of
morphological feature analysis and immunohistochemistry is useful
for screening of EML4-ALK-positive lung adenocarcinoma. J Clin
Pathol. 63:1066–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimada Y, Saji H, Nomura M, Matsubayashi
J, Yoshida K, Kakihana M, Kajiwara N, Ohira T and Ikeda N: Cancer
stem cell-related marker expression in lung adenocarcinoma and
relevance of histologic subtypes based on IASLC/ATS/ERS
classification. Onco Targets Ther. 6:1597–1604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kosaka T, Yatabe Y, Onozato R, Kuwano H
and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53
gene mutations in a large cohort of Japanese patients with
surgically treated lung adenocarcinoma. J Thorac Oncol. 4:22–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou
LJ, Yan H, Ye JW and Liu Y: Expression of MET and SOX2 genes in
non-small cell lung carcinoma with EGFR mutation. Oncol Rep.
26:877–885. 2011.PubMed/NCBI
|
|
22
|
Franklin WA, Haney J, Sugita M, Bemis L,
Jimeno A and Messersmith WA: KRAS mutation: Comparison of testing
methods and tissue sampling techniques in colon cancer. J Mol
Diagn. 12:43–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu DP, Dong YJ, Zhang HQ, Wang JH, Qu Y,
Zhou LJ, Su D, Zhang LL, Zhao D and Cai YR: Differential expression
of CRKL and AXL genes in lung adenocarcinoma subtypes according to
the epidermal growth factor receptor and anaplastic lymphoma kinase
gene status. Biomed Rep. 2:481–489. 2014.PubMed/NCBI
|
|
24
|
Song Z, Zhu H, Guo Z, Wu W, Sun W and
Zhang Y: Correlation of EGFR mutation and predominant histologic
subtype according to the new lung adenocarcinoma classification in
Chinese patients. Med Oncol. 30:6452013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsuta K, Kawago M, Inoue E, Yoshida A,
Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H
and Tsuda H: The utility of the proposed IASLC/ATS/ERS lung
adenocarcinoma subtypes for disease prognosis and correlation of
driver gene alterations. Lung cancer. 81:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu
G, Su D, Li X, Qin N, Nong J, et al: Clinicopathologic
characteristics of ALK rearrangements in primary lung
adenocarcinoma with identified EGFR and KRAS status. J Cancer Res
Clin Oncol. 140:453–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y,
Luo X, Ye T, Wang R, Hu H, et al: Frequency of driver mutations in
lung adenocarcinoma from female never-smokers varies with
histologic subtypes and age at diagnosis. Clin Cancer Res.
18:1947–1953. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kakegawa S, Shimizu K, Sugano M, Miyamae
Y, Kaira K, Araki T, Nakano T, Kamiyoshihara M, Kawashima O and
Takeyoshi I: Clinicopathological features of lung adenocarcinoma
with KRAS mutations. Cancer. 117:4257–4266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rekhtman N, Ang DC, Riely GJ, Ladanyi M
and Moreira AL: KRAS mutations are associated with solid growth
pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
Mod Pathol. 26:1307–1319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ignatius SH, Ziogas A and Zell JA: Primary
signet-ring carcinoma (SRC) of the lung: A population-based
epidemiologic study of 262 cases with comparison to adenocarcinoma
of the lung. J Thorac Oncol. 5:420–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gainor JF, Varghese AM, Ou SH, Kabraji S,
Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ,
et al: ALK rearrangements are mutually exclusive with mutations in
EGFR or KRAS: An analysis of 1,683 patients with non-small cell
lung cancer. Clin Cancer Res. 19:4273–4281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang X, Zhang S, Yang X, Yang J, Zhou Q,
Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is
associated with development of lung adenocarcinomas lacking EGFR
and KRAS mutations and is correlated with ALK expression. Mol
Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
|
